Drug
Nerandomilast
Nerandomilast: highest development phase Phase 3, developed by Boehringer Ingelheim. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Boehringer Ingelheim
Trials
| Drug | Phase | Indication |
|---|---|---|
| Nerandomilast NCT07789015 | Phase 3 | Idiopathic Inflammatory Myopathies |
| Nerandomilast NCT07366034 | Phase 3 | Fibrosing Interstitial Lung Disease |
Latest
No recent events.
Follow Nerandomilast on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.